Orchestra BioMed Holdings, Inc. logo

Orchestra BioMed Holdings, Inc. (OBIO) Q1 2025 Annual Earnings

OBIO·Reported April 2, 2025·Before market open

Orchestra BioMed Holdings, Inc. reported Q1 2025 revenue of $253.0K (-59.2% YoY), missed analyst consensus of $522.3K by $269.3K. Diluted EPS came in at $-0.43 (-13.2% YoY).

Revenue
$253.0Kmissed by $269.3K
Consensus: $522.3K
Diluted EPS
$-0.43met estimate
Consensus: $-0.43
SEC

SEC Filings

Earnings release8-K not filed yet
Annual report10-K · 0001558370-25-004161

Financial Snapshot

Trailing eight quarters through Q1 2025

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q1 2025 Earnings FAQ

Common questions about Orchestra BioMed Holdings, Inc.'s Q1 2025 earnings report.

Orchestra BioMed Holdings, Inc. (OBIO) reported Q1 2025 earnings on April 2, 2025 before market open.

Orchestra BioMed Holdings, Inc. reported revenue of $253.0K and diluted EPS of $-0.43 for Q1 2025.

Revenue missed the consensus estimate of $522.3K by $269.3K. EPS beat the consensus estimate of $-0.43 by $0.00.

Compared to the same quarter a year prior, revenue declined 59.2% from $620.0K a year earlier and diluted EPS declined 13.2% from $-0.38.

You can read the 10-K periodic report (0001558370-25-004161) directly on SEC EDGAR. The filing index links above go to sec.gov.